All Updates

All Updates

icon
Filter
Funding
Listing
Albert Labs raises CAD 4.7 million via private placement; goes public on CSE
Psychedelic Medicine
Mar 10, 2022
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Psychedelic Medicine

Psychedelic Medicine

Mar 10, 2022

Albert Labs raises CAD 4.7 million via private placement; goes public on CSE

Funding
Listing

  • Vancouver-based psychedelic medicine company Albert Labs began trading its common shares on the Canadian Securities Exchange (CSE) under the ticker symbol “ABRT” on March 10, 2022. 

  • The listing comes in conjunction with the completion of the previously announced reverse take-over (RTO) of ME. Resource Corp. (MEC). The company also closed a debt settlement and private placement offering of 18.9 million common shares at a rate of CAD 0.25 (USD 0.20) per share, raising gross proceeds of CAD 4.7 million (USD 3.7 million). 

  • The proceeds from the placement and the company’s existing cash balance will be used to manufacture and distribute its natural psilocybin-based prescription drug KRN-101 for clinical trials and carry out real-world evidence (RWE) trials together with partners.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.